clinical trial · NCT05239741
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 100
Colorectal NeoplasmsPembrolizumabOxaliplatinLeucovorin5-fluorouracilIrinotecanBevacizumabCetuximab
brief summary
In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study.
started
Apr 2, 2022
primary completion
Sep 19, 2028
completion
Sep 19, 2028
last updated
Apr 24, 2026
official title
A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol